Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus FACTIVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus FACTIVE.
CIPROFLOXACIN EXTENDED RELEASE vs FACTIVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
500-1000 mg orally once daily for 7-14 days; extended-release tablet must be taken whole with a meal.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
None Documented
None Documented
Terminal elimination half-life approximately 11 hours, ranging from 10-14 hours in patients with normal renal function. Prolonged in renal impairment; requires dose adjustment.
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Primarily renal excretion (50-70% unchanged drug via glomerular filtration and tubular secretion); 15-25% metabolized; 20-35% fecal elimination via biliary secretion and intestinal epithelium.
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic